• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·PEHA.JK
Share

PT Phapros, Tbk Stocks

IDR 278Last Updated 23.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

IDR 12.80M

IDR 278
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Phapros, Tbk is a prominent Indonesian company operating within the pharmaceutical and healthcare sectors. Its operations are broadly categorized into four key divisions: Over-the-Counter (OTC) products, Ethical drugs, Generic drug manufacturing, and Toll Manufacturing services. The company's OTC offerings feature well-known brands such as Antimo Anak, Livron B Plek, Noza, Hemorogard, and Bioron. In addition to supplying generic medications to government institutions and hospitals, PT Phapros also serves as a contract manufacturer for other pharmaceutical companies and provides various medical devices. Established in 1954 with its headquarters located in Jakarta, Indonesia, the company further extends its market reach by exporting products internationally. PT Phapros, Tbk functions as a subsidiary under the umbrella of PT Kimia Farma (Persero) Tbk.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 09:00

Apollo and Morgan Stanley have once again restricted withdrawals from private credit funds

24.06.2026 08:00

Alibaba has filed a lawsuit against the Pentagon over allegations of ties to the Chinese military

24.06.2026 07:00

Alphabet will be added to the Dow Jones Blue Chip Index. Its stock price has doubled over the past year

24.06.2026 01:47

The boom in the prediction market has prompted Meta to create its own app — NYT

24.06.2026 01:09

The Nasdaq fell 2%, with volatility hitting a two-year high: a look back at the day's sell-off in the tech sector

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026